Investor Relations

Annual Meeting of Shareholders

  o Directions to CEL-SCI's Annual Meeting  
       

Stock Quote - Ticker Tape

 

SEC Filings

  o View CEL-SCI's SEC Filings  
       

CEL-SCI Presentations

  June 17, 2015
CEO Presentation at 2015 BIO International Convention

 
  May 27, 2015
CEO Presentation at 2015 Marcum Microcap Conference

 
  February 2015
Exclusive Interview with Geert Kersten from the floor of the NYSE

 

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o All Press Releases  
 
  JULY 1, 2015
NEW STORY CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial
  JUNE 16, 2015
NEW STORY CEL-SCI to Present at the 2015 Bio International Convention
  JUNE 8, 2015
NEW STORY CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in Thailand
  JUNE 1, 2015
NEW STORY CEL-SCI Reports May Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial
  MAY 29, 2015
NEW STORY CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $16 Million
  MAY 13, 2015
NEW STORY CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Italy
  MAY 11, 2015
NEW STORY CEL-SCI Receives Authorization to Conduct Its Phase 3 Multikine Trial in Spain
  MAY 8, 2015
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2015 Financial Results
  MAY 6, 2015
NEW STORY CEL-SCI Announces Proposed Public Offering of Common Stock
  MAY 1, 2015
NEW STORY CEL-SCI Reports 4th Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial
  APRIL 13, 2015
NEW STORY UK's Aintree University Hospital Joins CEL-SCI's Phase III Head and Neck Cancer Trial
  APRIL 1, 2015
NEW STORY CEL-SCI Reports 3rd Consecutive Month of Record Patient Enrollment in 2015 for Its Phase III Head and Neck Cancer Trial

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com